Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures

Veerle A.B. van den Bogaard, Bastiaan D.P. Ta, Arjen van der Schaaf, Angelique B. Bouma, Astrid M.H. Middag, Enja J. Bantema-Joppe, Lisanne V. van Dijk, Femke B.J. van Dijk-Peters, Laurens A.W. Marteijn, Gertruida H. de Bock, Johannes G.M. Burgerhof, Jourik A. Gietema, Johannes A. Langendijk, John H. Maduro, and Anne P.G Crijns

ABSTRACT

Purpose
A relationship between mean heart dose (MHD) and acute coronary event (ACE) rate was reported in a study of patients with breast cancer (BC). The main objective of our cohort study was to validate this relationship and investigate if other dose-distribution parameters are better predictors for ACES than MHD.

Patients and Methods
The cohort consisted of 910 consecutive female patients with BC treated with radiotherapy (RT) after breast-conserving surgery. The primary end point was cumulative incidence of ACES within 9 years of follow-up. Both MHD and various dose-distribution parameters of the cardiac substructures were collected from three-dimensional computed tomography planning data.

Results
The median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy). The median follow-up time was 7.6 years (range, 0.1 to 10.1 years), during which 30 patients experienced an ACE. The cumulative incidence of ACES increased by 16.5% per Gy (95% CI, 0.6 to 35.0; \( P = .042 \)). Analysis showed that the volume of the left ventricle receiving 5 Gy (LV-V5) was the most important prognostic dose-volume parameter. The most optimal multivariable normal tissue complication probability model for ACES consisted of LV-V5, age, and weighted ACE risk score per patient (c-statistic, 0.83; 95% CI, 0.75 to 0.91).

Conclusion
A significant dose-effect relationship was found for ACES within 9 years after RT. Using MHD, the relative increase per Gy was similar to that reported in the previous study. In addition, LV-V5 seemed to be a better predictor for ACES than MHD. This study confirms the importance of reducing exposure of the heart to radiation to avoid excess risk of ACES after radiotherapy for BC.

INTRODUCTION

The number of breast cancer (BC) survivors is increasing as a result of rising incidence, earlier diagnosis, and better treatment results.\(^1\)\(^,\)\(^2\) Although adjuvant radiotherapy (RT) after surgery for BC improves locoregional control and overall survival, incidental exposure of the heart to radiation increases the risk of RT-induced cardiac toxicity.\(^3\)\(^,\)\(^5\) Consequently, the prevalence of BC survivors at risk for long-term RT-induced cardiac toxicity is increasing and may have a significant impact on health-related quality of life.

Darby et al\(^6\) demonstrated a dose-effect relationship based on the mean heart dose (MHD) to the whole heart. They found a relative increase of 7.4% per Gy of MHD in the rate of major acute coronary events (ACES) for the entire follow-up period. Confining the analysis to the first 9 years after radiation exposure, a relative increase of approximately 16% per Gy was found. However, the study had some limitations: its design (case-control study), use of outdated RT technologies, and
use of reconstructed MHDs derived from two-dimensional data.

Therefore, the first aim of our study was to validate the findings of Darby et al5 with an independent cohort of consecutive patients with BC based on individual three-dimensional (3D) dose distributions derived from computed tomography (CT) planning scans. The second aim of this cohort study was to investigate whether other dose-distribution parameters could better predict the excess risk of ACEs after RT in individual patients with BC compared with MHD.

**PATIENTS AND METHODS**

**Study Population**

This study population was composed of a consecutive series of female patients with BC treated with RT after breast-conserving surgery for stage I to III invasive adenocarcinoma or carcinoma in situ from January 2005 to December 2008 in our hospital (Appendix Fig A1, online only). Patients with BC were eligible for inclusion only if CT-based RT planning data were available. Patients were excluded if they had a history of other malignancies or had received prior RT or treatment with neoadjuvant chemotherapy. The primary end point was an ACE, defined as a diagnosis of myocardial infarction (International Classification of Diseases, 10th Revision, codes 121 to 124), coronary revascularization, or death resulting from ischemic heart disease (codes 120 to 125) after completion of treatment. Pretreatment risk factors for ACEs that were taken into account included history of ischemic heart disease, any other cardiac disease, hypertension, chronic obstructive pulmonary disease, pulmonary embolism, diabetes, current smoker status, and body mass index $\geq 30$ kg/m². Both the end point and pretreatment risk factors were similar to those defined by Darby et al.6

**Data Collection**

Patient characteristics, treatment plans, follow-up data, and information on cardiac risk factors and cardiac end points were retrospectively extracted from patient records of the Department of Radiation Oncology (University Medical Center Groningen, University of Groningen, Groningen, the Netherlands). Incomplete patient data were supplemented with information derived from general practitioners’ (GPs’) records. To this end, surviving patients were informed about the study by letter and asked for their written informed consent. GPs of deceased patients were allowed to provide relevant information directly, because GPs have legal governance over deceased patients’ records in the Netherlands. The aforementioned procedure was approved by the medical ethical committee of the University Medical Center Groningen.

**Data Definitions**

The baseline date was defined as the first day of breast irradiation. Patient event times were censored in cases where a new radiation treatment was delivered in the follow-up period, in cases of death, or at the end of follow-up time. The follow-up interval was defined as the time between baseline and censoring date or date of event. Patient information was collected until the last known date of medical follow-up or last known information obtained from the GP.

**Radiation Dosimetry**

Irradiation of the breast for all patients was performed with 3D conformal RT using CT-based planning, as described previously.7 All treatment plans were calculated using heterogeneity corrections. Beam configuration comprised tangential fields and additional beams for optimization of planning target volume coverage, as well as for minimization of the dose to the heart, lungs, and contralateral breast. A dose of 50.4 Gy was prescribed for the whole breast in 28 fractions, with a simultaneous integrated boost dose of 14 or 16.8 Gy in the same 28 fractions, depending on pathologic risk factors. The heart and its substructures, including the left ventricle (LV), left atrium, right ventricle, and right atrium, were recontoured with a multiatlas automatic segmentation tool of the heart developed in house based on the atlas by Feng et al (Mirada RTx [version 1.6]; Mirada Medical, Oxford, United Kingdom).8 Automatic segmentation reduces interobserver variability in contouring organs at risk and therefore generates more consistent data to create normal tissue complication probability (NTCP) models.9,10 With the delineated volumes, it was possible to calculate the exact planned radiation dose to the different volumes. This so-called dose-volume histogram showed the relationship between the dose in Gy to the volume percentage of the structure of interest.12,13 With the dose of the individual patients, the dose-effect relationship could be calculated independently of RT technique or treatment volume. Finally, the planned dose-distribution parameters for the whole heart and its substructures were extracted from our treatment planning system (Pinnacle [version 9.1]; Philips Radiation Oncology, Fitchburg, WI).

**Statistical Analysis**

The cumulative incidence of ACEs was analyzed using the Kaplan-Meier method. To validate the model of Darby et al,6 a multivariable Cox regression analysis was used, including the same risk factors and end point. Model performance was tested for calibration using the Hosmer-Lemeshow (HL) test, and discrimination was tested using the c-statistic.

The most relevant dose-distribution parameters for the different cardiac substructures were identified by comparing the mean dose-distribution parameters of patient cases (patients who experienced an ACE) with noncases (patients who did not). To this end, we calculated the mean $V(x)$ in bins of 5 Gy for both patient cases and noncases, where $V(x)$ refers to the relative volume (in percentage) of the heart or cardiac substructure that received $x$ Gy. Differences between the two groups regarding all mean dose-distribution parameters were tested with a $t$ test or Wilcoxon rank sum test whenever appropriate. The dichotomous variable (no risk factor v one or more risk factors) was replaced by a weighted ACE risk score per patient. To this end, we first investigated which risk factors were significantly associated with the incidence of ACEs by using univariable Cox regression analysis and then performed a multivariable analysis taking into account only the significant cardiac risk factors. For the risk factors that were significantly associated with ACEs in the multivariable analysis, the regression coefficients were calculated and used for the weighted sum of the risk factor(s) per patient. In correspondence with Darby et al,6 age was entered into the model as well. Because the number of events was limited, we decided not to add more than these three factors to the model to prevent overfitting.14,15 For internal validation and adjustment for possible internal optimism for both the c-statistics and some estimators, bootstrapping was performed by using 1,000 random subsets. Model performance was tested for calibration using the HL test. Finally, the excess risk of an ACE resulting from RT was calculated via the individual patient risk based on the model minus the individual patient risk assuming the LV receiving 5 Gy (LV-V5) received 0%. Calculations were performed SPSS software (version 22; SPSS, Chicago, IL).

**RESULTS**

**Patient Characteristics**

A total of 910 patients were included in this study. The characteristics of these patients are summarized in Table 1. The median age of all patients was 59 years (range, 26 to 84 years). At baseline, more than half of the patients had one or more risk factors...
The median follow-up time was 7.6 years (range, 0.1 to 10.1 years).

More detailed information about the distribution of MHD and the univariable analysis between MHD and the end point ACE is provided in Appendix Table A1 (online only), Appendix Figures A2 to A4 (online only), and Appendix Figure A5 (online only), and information about patients experiencing an event is listed in Appendix Table A2 (online only). In total, 30 patients (3.3%) developed an ACE during follow-up, 10 of whom died as a result of ischemic heart disease. In the first 5 years, 17 patients were diagnosed with ACEs. The 5- and 9-year cumulative incidences of ACEs were 1.9% (95% CI, 0.9% to 2.9%) and 3.9% (95% CI, 2.3% to 5.5%), respectively (Appendix Fig A6, online only).

Validation

To validate the model of Darby et al,6 a multivariable Cox regression model was created using the same prognostic factors (ie, age, MHD, and presence of pretreatment risk factors for ACEs, for ACEs. The median follow-up time was 7.6 years (range, 0.1 to 10.1 years).

More detailed information about the distribution of MHD and the univariable analysis between MHD and the end point ACE is provided in Appendix Table A1 (online only), Appendix Figures A2 to A4 (online only), and Appendix Figure A5 (online only), and information about patients experiencing an event is listed in Appendix Table A2 (online only). In total, 30 patients (3.3%) developed an ACE during follow-up, 10 of whom died as a result of ischemic heart disease. In the first 5 years, 17 patients were diagnosed with ACEs. The 5- and 9-year cumulative incidences of ACEs were 1.9% (95% CI, 0.9% to 2.9%) and 3.9% (95% CI, 2.3% to 5.5%), respectively (Appendix Fig A6, online only).

Validation

To validate the model of Darby et al,6 a multivariable Cox regression model was created using the same prognostic factors (ie, age, MHD, and presence of pretreatment risk factors for ACEs,
The mean predicted CI9y for the entire population was 4.0%, which was in agreement with the CI9y assuming an MHD of 0 Gy (CI9y-0Gy): CER9y = CI9y - CI9y-0Gy.

The HL test showed no significant difference between expected and observed rates of ACEs (P = .406), indicating good calibration. Model discrimination was good, with a c-statistic of .80 (95% CI, .72 to .88) within 9 years of RT (Table 2).

On the basis of this model, the 9-year excess cumulative risk (CER9y) can then be calculated using the following equations:

1. The linear predictor LPMHD-model = (0.153 × MHD) + (0.087 × AGE) + (1.821 × RISK), in which MHD = mean heart dose in Gy, AGE = age in years, and RISK = 1 if one or more risk factors at baseline are present.

2. The cumulative incidence for each individual patient at 9 years (CI9y) can then be calculated using the following equation: CI9y = 1 - [EXP(-0.000025 × EXP(LPMHD-model))].

3. The 9-year excess cumulative risk (CER9y) can then be calculated by using Equation 2 minus the CI9y assuming an MHD of 0 Gy (CI9y-0Gy): CER9y = CI9y - CI9y-0Gy.

The HI test showed no significant difference between expected and observed rates of ACEs (P = .406), indicating good calibration. Model discrimination was good, with a c-statistic of .80 (95% CI, .72 to .88). The mean predicted CI9y for the entire population was 4.0%, which was in agreement with the CI9y actually observed: 3.9%.

To get an impression of the early risk of ACEs, a model for the first 5 years after RT (Table 2) was tested separately. Using the same risk factors and end point as those of Darby et al, an increase of 24.6% in the rate of ACEs per Gy of MHD was found for the complete follow-up period of 5 years.

### Model Optimization

To identify the most relevant dose-distribution parameters, we compared the mean dose parameters of the patient cases (patients who experienced an ACE) with noncases (patients who did not). Figure 1 shows the differences between the mean dose-distribution parameters per cardiac substructure that were tested for significance. The largest difference was found for LV-V5. In the univariable Cox regression analysis, summarized in Table 3, LV-V5 was significantly associated with the cumulative incidence of ACEs, with a hazard ratio of 1.016 (95% CI, 1.002 to 1.030; P = .016). Because of this strong association, we chose to include LV-V5 in the model. Replacement of MHD with LV-V5 resulted in an improvement of the c-statistic of the NTCP model to 0.80 (95% CI, 0.72 to 0.88). We also tested the relationship of the maximum dose to the heart with the cumulative incidence of ACEs using a univariable Cox regression.
analysis and found it was not significantly associated with ACEs (data not shown).

To further optimize the NTCP model based on LV-V5, the dichotomous variable (no risk factor vs one or more risk factors) was replaced with a weighted ACE risk score per patient. Because there were only 30 events, LV-V5, age, and weighted ACE risk score per patient based on the regression coefficient of the significant risk factors for ACEs (0.8 for diabetes, 1.4 for hypertension, and 1.8 for history of ischemic cardiac events) were entered into the multivariable model. The final multivariable NTCP model summarized in Table 3 is corrected for optimism.

On the basis of this model, the 9-year excess cumulative risk can be calculated using the following equations:

1. The linear predictor $LPL_{LV-V5-model} = (0.017 \times LV-V5) + (0.063 \times AGE) + (0.711 \times RISKSCORE)$, in which LV-V5 = LV-V5 in %, AGE = age in years, and RISKSCORE = weighted ACE risk score (0 for no risk factors; add 0.8 in case of diabetes, add 1.4 in case of hypertension, and add 1.8 in case of ischemic cardiac events before RT).

2. The cumulative incidence for each individual patient at 9 years ($CI_{9y}$) can then be calculated using the following equation:

$$CI_{9y} = 1 - \exp(-0.000223 \times \exp(LPL_{LV-V5-model}))$$

3. The 9-year excess cumulative risk ($CER_{9y}$) can then be calculated by using Equation 2 minus the $CI_{9y}$ assuming an LV-V5 of 0% ($CI_{9y-0Gy}$):

$$CER_{9y} = CI_{9y} - CI_{9y-0Gy}$$

The mean predicted $CI_{9y}$ for the entire population was 3.5%, which was in agreement with the $CI_{9y}$ actually observed: 3.9%. This modified model showed good agreement between expected and observed rates of ACEs (HL test $P = .380$). Discrimination of the final model in terms of the c-statistic showed good results at 0.83 (95% CI, 0.75 to 0.91), which was significantly better than that in the MHD model ($P = .042$).

### Table 3. Univariable and Multivariable NTCP Models for Cumulative Incidence of ACEs Within First 9 Years After RT After Correction for Overfitting

| Variable            | Univariable analysis LV-V5 | Final multivariable NTCP model |
|---------------------|-----------------------------|---------------------------------|
| LV-V5*              | 0.016 0.007 1.016 1.002 to 1.030 .016 | LV-V5* 0.017 0.009 1.017 0.999 to 1.036 .041 |
| Final multivariable NTCP model | Age 0.063 0.026 1.065 1.014 to 1.116 .010 | Weighted ACE risk score 0.711 0.187 2.036 1.669 to 2.403 .001 |

Abbreviations: ACE, acute coronary event; HR, hazard ratio; LV-V5, left-ventricle receiving 5 Gy; NTCP, normal tissue complication probability; RT, radiotherapy.

*Relative volume of LV-V5 based on individual three-dimensional dose-volume data obtained from computed tomography planning scans.

![Fig 2](https://example.com/fig2.png)

**Fig 2.** Excess risk of an acute coronary event (ACE) depending on the mean heart dose (MHD) in volume percentage calculated per age category and (A) absence or (B) presence of cardiac risk factors.
The excess cumulative risk related to RT was 1.13% within 9 years of follow-up, indicating that approximately 10 patients in this BC cohort experienced an ACE that could be attributed to RT. The excess risk for the occurrence of an ACE, depending on the mean dose, is shown in Figure 2 and based on the LV-V5 in Figure 3.

DISCUSSION

To our knowledge, this is the first study to validate the model published by Darby et al in an independent cohort using individual 3D CT planning data. Using exactly the same risk factors and end point as Darby et al, we found an increase of 16.5% (95% CI, 0.6 to 35.0) in the cumulative incidence of ACEs per Gy of radiation to the whole heart in the first 9 years after treatment. These results are consistent with the hazard ratios of 16.3% increase per Gy, as observed by Darby et al in the first 4 years of follow-up, and 15.5% increase in the next 5 to 9 years after RT. Furthermore, our study suggests that the NTCP model for ACEs could be improved by using LV-V5 instead of MHD. Model performance showed good results in terms of calibration and discrimination.

An NTCP model is a term generally used in radiation oncology, which refers to any prediction model describing the relationship between 3D dose-distribution parameters of normal tissues and a complication end point. In radiotherapy, NTCP models are generally used to estimate the risks of adverse effects, as well as to optimize dose distributions for individual patients by minimizing the most relevant dose metrics derived from NTCP models. To enhance the clinical utility of prediction models, it is highly recommended that the performance of the model be evaluated in an independent data set. Despite differences with regard to study design (case-control vs cohort study), irradiation technique, estimated dose distributions (reconstructed MHD vs 3D planning CT based), timeframe, and nationality, the results found in our study are in line with those reported by Darby et al. Therefore, the model summarized in Table 2 can be considered as
a TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) type IV prediction model, the performance of which has been evaluated in an independent data set.\(^1\) The results of case-control studies, as reported by Darby et al, provide only relative risk against baseline risk, which requires other prediction models to assess these baseline risks. Because our multivariable externally validated model (Table 2) was based on a cohort study, it allows for a direct risk estimation of ACEs for individual patients with BC. However, because we were not able to externally validate the LV-V5 model, this model should be regarded as TRIPOD type Ib, which requires external validation first before it can be used in routine clinical practice.

Our dose-distribution analysis (Fig 1) showed that the LV received the highest dose of all cardiac structures, which is mainly because of the anatomic location of the LV in relation to the breasts and treatment technique, which may increase statistical power. The analysis comparing the dose-distribution parameters between patient cases and noncases also revealed large differences, even for lower dose levels (eg, LV-V2 to -V4; data not shown). LV-V5 was eventually chosen because this dose-distribution parameter has been widely used in many other recent reports.\(^18\)-\(^22\)

As shown in a recent study, heart doses from RT for BC vary widely, even among seemingly similar regimens.\(^23\) Therefore, we chose to use an automatic delineation tool to exclude interobserver variability.\(^5,24\) Furthermore, we used individual dose-volume data, which account for differences in anatomy and treatment volume.

It has long been assumed that the clinical events of incidental cardiac irradiation occur after more than 10 years.\(^25\)-\(^29\) One of the biologic mechanisms leading to radiation-induced ACEs is accelerated atherosclerosis.\(^30\)-\(^32\) However, in our analysis, a dose-effect relationship was found for events occurring within the first 5 years after radiation exposure. This early risk is consistent with that reported by Darby et al\(^6\) and that seen in other research in patients with Hodgkin lymphoma.\(^33\) However, other studies found only a small effect in 6 to 10 years after treatment, when the internal mammary vessels were not treated.\(^34\),\(^35\) When these nodes were treated, the occurrence of cardiac damage was found within 5 years.\(^36\) Given these results, and setting aside the relatively slowly progressing phenomenon of atherosclerosis, other biologic mechanisms are most likely responsible for the relatively early cardiac events occurring after RT (eg, microvascular damage, impairment in myocardial perfusion and/or fatty acid metabolism, and many more).\(^37\)-\(^41\) Studies investigating these underlying mechanisms for early RT-induced cardiac damage using modern imaging techniques are currently under way.\(^42\)

A limitation of our study is the relatively small number of ACEs. Because 3D conformal RT at our hospital was clinically introduced in 2005, the follow-up time was relatively short.

To prevent overfitting by using too many candidate variables in relation to the number of events, we included only two other prognostic factors, besides the dose-distribution parameter: clinical risk factors for ACEs and age, based on the fact that these are considered the most important predictors for ACEs.\(^43\) Consequently, the effects of other potential confounders could not be taken into account, such as the addition of systemic agents that could also cause cardiac toxicity.\(^44\),\(^45\)

In conclusion, the MHD-based NTCP model for ACEs has been independently validated using 3D dose-distribution data among patients with BC treated with postoperative RT. Radiation dose to the heart is an important risk factor for ACEs in BC survivors. Model performance was significantly improved by replacing MHD with LV-V5 and using the weighted ACE risk score, but this optimized model requires further external validation in an independent data set.

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at jco.org.

**AUTHOR CONTRIBUTIONS**

Conception and design: Veerle A.B. van den Bogaard, Bastiaan D.P. Ta, Arjen van der Schaaf, Angelique B. Bouma, Astrid M.H. Middag, Enja J. Bantema-Joppe, Femke B.J. van Dijk-Peters, Johannes A. Langendijk, John H. Maduro, Anne P.G. Crijns

Collection and assembly of data: Veerle A.B. van den Bogaard, Bastiaan D.P. Ta, Angelique B. Bouma, Astrid M.H. Middag, Enja J. Bantema-Joppe, Lisanne V. van Dijk, Laurens A.W. Marteijn

Data analysis and interpretation: Veerle A.B. van den Bogaard, Arjen van der Schaaf, Astrid M.H. Middag, Gertruidia H. de Bock, Johannes G.M. Burgerhof, Jourik A. Gietema, Johannes A. Langendijk, John H. Maduro, Anne P.G. Crijns

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

**REFERENCES**

1. Clarke M, Collins R, Darby S, et al: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 366:2087-2106, 2005
2. Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378: 1707-1716, 2011
3. Zagar TM, Marks LB: Breast cancer: Risk of heart disease after radiotherapy—cause for concern. Nat Rev Clin Oncol 10:310-312, 2013
4. Boero LJ, Paravati AJ, Tripplett DP, et al: Modern radiation therapy and cardiac outcomes in breast cancer. Int J Radiat Oncol Biol Phys 94: 700-708, 2016
5. Boekel NB, Schaapveld M, Gietema JA, et al: Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys 94:1061-1072, 2016
6. Darby SC, Ewertz M, McGale P, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368:987-998, 2013
7. van der Laan HP, Dolans W V, Maduro JH, et al: Dosimetric consequences of the shift towards computed tomography guided target definition and planning for breast conserving radiotherapy. Radiother Oncol 3:6, 2008
8. Feng M, Moran JM, Koelling T, et al: Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10-18, 2011
9. Van Dijk-Peters FBJ, Sijtsema NM, Kierkels RGJ, et al: Validation of a multi-atlas based automatic segmentation of the heart in breast cancer patients. Radiother Oncol 115:S132-S133, 2015 (abstr OC-0259)
van den Bogaard et al

10. Chen A, Niemann KJ, Deele MA, et al: Evaluation of multiple-atlas-based strategies for segmentation of the thyroid gland in head and neck CT images for IMRT. Phys Med Biol 57:93-111, 2012
11. Klein S, van der Heide UA, Lips IM, et al: Automatic segmentation of the prostate in 3D MR images by atlas matching using localized mutual information. Med Phys 35:1407-1417, 2008
12. Drzymala RE, Mohan R, Brewer W, et al: Dose-volume histograms. Int J Radiat Oncol Biol Phys 21:71-76, 1991
13. Pyakuryal A, Myint WK, Gopalakrishnan M, et al: A computational tool for the efficient analysis of dose-volume histograms from radiation therapy treatment plans. J Appl Clin Med Phys 11:3013, 2010
14. Concoato J, Peduzzi P, Holford TR, et al: Importance of events per independent variable in proportional hazards analysis: I. Background, goals, and general strategy. J Clin Epidemiol 48:1496-1501, 1995
15. Peduzzi P, Concoato J, Feinstein AR, et al: Importance of events per independent variable in proportional hazards regression analysis: II. Accuracy and precision of regression estimates. J Clin Epidemiol 48:1503-1510, 1995
16. Langendijk JA, Lambin P, De Ruyscher D, et al: Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. Radiother Oncol 107:267-273, 2013
17. Collins GS, Reitsma JB, Altman DG, et al: Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD): The TRIPOD statement. Eur Urol 67:1142-1151, 2015
18. Kuo AH, Ancukiewicz M, Kozak KR, et al: Cardiac and inflammatory biomarkers do not correlate with volume of heart or lung receiving radiation. Radiat Oncol 10:5, 2015
19. Marks LB, Bentzen SM, Deasy JO, et al: Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 76:S70-S76, 2010 (suppl 1)
20. Lin A, Shaieff W, Juhass J, et al: The benefit of deep inspiration breath hold. Evaluating cardiac radiation exposure in patients after mastectomy and after breast-conserving surgery. Breast Cancer (epub ahead of print on February 17, 2016)
21. Miles EF, Larrier NA, Kelsey CR, et al: Intensity-modulated radiotherapy for resected mesothelioma: The Duke experience. Int J Radiat Oncol Biol Phys 71:1143-1150, 2008
22. Bradley JA, Dagan R, Ho MW, et al: Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons. Int J Radiat Oncol Biol Phys 95:411-421, 2016
23. Taylor CW, Wang Z, Macaulay E, et al: Exposure of the heart in breast cancer radiation therapy: A systematic review of heart doses published during 2003 to 2013. Int J Radiat Oncol Biol Phys 93:845-853, 2015
24. Lorenzen EL, Taylor CW, Maraldo M, et al: Inter-observer variation in delineation of the heart and left anterior descending coronary artery in radiotherapy for breast cancer: A multi-centre study from Denmark and the UK. Radiother Oncol 108:254-258, 2013
25. Magné N, Chargari C, MacDermed D, et al: Tomorrow’s targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol 76:186-195, 2010
26. Goethals I, Dierckx R, De Meerleer G, et al: The role of nuclear medicine in the prediction and detection of radiation-associated normal pulmonary and cardiac damage. J Nucl Med 44:1531-1539, 2003
27. Evans SB, Isahanshi S, Moran MS, et al: Prevalence of poor cardiac anatomy in carcinoma of the breast treated with whole-breast radiotherapy: Reconciling modern cardiac dosimetry with cardiac mortality data. Am J Clin Oncol 35:587-592, 2012
28. Lee LJ, Harris JR: Innovations in radiation therapy (RT) for breast cancer. Breast 18:S103-S111, 2009 (suppl 3)
29. Darby SC, MacGale P, Taylor CW, et al: Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557-565, 2005
30. Plummer C, Henderson RD, O’Sullivan JD, et al: Ischemic stroke and transient ischemic attack after head and neck radiotherapy: A review. Stroke 42:2410-2418, 2011
31. Correa CR, Litt HI, Hwang W-T, et al: Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol 25:3031-3037, 2007
32. Nilsson G, Holmberg L, Garmo H, et al: Distribution of coronary artery stenosis after radiation for breast cancer. J Clin Oncol 30:380-386, 2012
33. Heidenreich PA, Schnittger I, Strauss HW, et al: Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 25:43-49, 2007
34. Valls KA, Pintilie M, Chong N, et al: Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 20:1036-1042, 2002
35. Harris EER, Correa C, Hwang W-T, et al: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 24:4100-4106, 2006
36. Hooning MJ, Aleman BMP, van Rosmalen AJM, et al: Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 64:1081-1091, 2006
37. Yan R, Song J, Wu Z, et al: Detection of myocardial metabolic abnormalities by 18F-FDG PET/CT and corresponding pathological changes in beagles with local heart irradiation. Korean J Radiol 16:919-928, 2015
38. Jingu K, Kaneta T, Nemoto K, et al: The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. Int J Radiat Oncol Biol Phys 86:845-851, 2006
39. Byrd BF III, Mendes LA: Cardiac complications of mediastinal radiotherapy: The other side of the coin. J Am Coll Cardiol 42:750-751, 2003
40. Lauk S, Kiszal Z, Buschmann J, et al: Radiation-induced heart disease in rats. Int J Radiat Oncol Biol Phys 11:801-808, 1985
41. Erven K, Jurgut R, Weltens C, et al: Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients. Int J Radiat Oncol Biol Phys 79:1444-1451, 2011
42. Jacob S, Pathak A, Franck D, et al: Early detection and prediction of cardiotoxicity after radiotherapy for breast cancer: The BACCARAT prospective cohort study. Radiat Oncol 11:54, 2016
43. Piepoli MF, Hoes AW, Agewall S, et al: European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)—Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37:2315-2381, 2016
44. Ky B, Vejpongsa P, Yeh ETH, et al: Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 113:754-764, 2013
45. Yeh ETH, Bickford CL: Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231-2247, 2009

Affiliations
All authors: University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Prior Presentation
Presented orally at the Annual Meeting of the American Society for Radiation Oncology, Boston, MA, September 25-28, 2016.
### AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

**Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jco/site/ifc](http://ascopubs.org/jco/site/ifc).

| Author                                | Relationship to Disclose |
|---------------------------------------|--------------------------|
| Veerle A.B. van den Bogaard           | No relationship to disclose |
| Bastiaan D.P. Ta                      | No relationship to disclose |
| Arjen van der Schaaf                  | No relationship to disclose |
| Angelique B. Bouma                    | No relationship to disclose |
| Astrid M.H. Middag                    | No relationship to disclose |
| Enja J. Bantema-Joppe                 | No relationship to disclose |
| Lisanne V. van Dijk                   | No relationship to disclose |
| Femke B.J. van Dijk-Peters            | No relationship to disclose |
| Laurens A.W. Marteijn                 | No relationship to disclose |
| Gertruida H. de Bock                  | No relationship to disclose |
| Johannes G.M. Burgerhof               | No relationship to disclose |
| Jourik A. Gietema                     | Research Funding: Roche (Inst), AbbVie (Inst), Siemens (Inst) |
| Johannes A. Langendijk                | Honoraria: IBA |
|                                       | Consulting or Advisory Role: IBA |
|                                       | Speakers’ Bureau: IBA |
|                                       | Research Funding: RaySearch Laboratories (Inst), IBA (Inst), Philips Healthcare (Inst), Mirada (Inst) |
| John H. Maduro                        | No relationship to disclose |
| Anne P.G. Crijns                      | No relationship to disclose |
### Table A1. MHD in Relation to Patient Clinical Characteristics at Baseline

| Characteristic                                      | Median (range) | MHD | Total | Left-Sided BC | Right-Sided BC |
|-----------------------------------------------------|----------------|-----|-------|---------------|---------------|
| **Age at BC diagnosis, years**                       |                |     |       |               |               |
| 18-35                                               | 2.34 (0.98-12.68) |     | 4.39 (1.08-12.68) | 1.26 (0.98-2.37) |
| 36-45                                               | 2.29 (0.63-13.75) |     | 4.73 (1.85-13.75) | 1.32 (0.63-3.19) |
| 46-55                                               | 1.99 (0.51-12.37) |     | 4.58 (1.27-12.37) | 1.32 (0.51-3.63) |
| 56-65                                               | 2.57 (0.62-15.25) |     | 4.48 (1.17-15.25) | 1.32 (0.62-6.87) |
| 66-75                                               | 2.31 (0.67-10.81) |     | 4.12 (0.99-10.81) | 1.31 (0.67-4.46) |
| 76 and up                                           | 2.99 (0.75-9.48) |     | 4.42 (1.48-9.48) | 1.25 (0.75-3.95) |
| **No. of risk factors for ACE at baseline**          |                |     |       |               |               |
| 0                                                   | 2.35 (0.62-15.25) |     | 4.66 (1.08-15.25) | 1.35 (0.62-6.87) |
| 1                                                   | 2.38 (0.51-13.75) |     | 4.19 (0.99-13.75) | 1.28 (0.51-4.46) |
| **History of (cardiac) comorbidity**                |                |     |       |               |               |
| Ischemic heart disease†                              | 3.22 (0.67-6.55) |     | 3.81 (1.81-6.55) | 1.24 (0.67-4.12) |
| Yes                                                 | 2.35 (0.51-15.25) |     | 4.48 (0.99-15.25) | 1.31 (0.51-6.87) |
| No                                                  | 2.45 (1.19-8.92) |     | 2.98 (1.81-8.92) | 1.92 (1.19-4.12) |
| Heart failure                                       | 2.37 (0.51-15.25) |     | 4.44 (0.99-15.25) | 1.31 (0.51-6.87) |
| Yes                                                 | 2.65 (0.64-7.47) |     | 4.97 (2.24-7.47) | 1.56 (0.64-4.12) |
| No                                                  | 2.35 (0.51-15.25) |     | 4.41 (0.99-15.25) | 1.31 (0.51-6.87) |
| Cardiac valve disease                               |                |     |       |               |               |
| Yes                                                 | 2.68 (0.51-11.22) |     | 4.45 (0.99-11.22) | 1.27 (0.51-4.12) |
| No                                                  | 2.26 (0.62-15.25) |     | 4.42 (1.08-15.25) | 1.33 (0.62-6.87) |
| **COPD§**                                           |                |     |       |               |               |
| Yes                                                 | 2.39 (0.64-9.35) |     | 3.30 (1.27-9.35) | 1.38 (0.64-3.96) |
| No                                                  | 2.36 (0.51-15.25) |     | 4.49 (0.99-15.25) | 1.31 (0.51-6.87) |
| **Pulmonary embolism**                              |                |     |       |               |               |
| Yes                                                 | 2.35 (0.72-5.58) |     | 5.26 (2.35-5.58) | 1.19 (0.72-1.56) |
| No                                                  | 2.37 (0.51-15.25) |     | 4.43 (0.99-15.25) | 1.31 (0.51-6.87) |
| **Diabetes¶**                                       |                |     |       |               |               |
| Yes                                                 | 3.30 (0.68-8.92) |     | 4.55 (2.65-8.92) | 1.23 (0.68-3.96) |
| No                                                  | 2.33 (0.51-15.25) |     | 4.44 (0.99-15.25) | 1.32 (0.51-6.87) |
| **Lifestyle risk factors at baseline**               |                |     |       |               |               |
| Current smoker                                       |                |     |       |               |               |
| Yes                                                 | 1.99 (0.64-13.75) |     | 3.92 (1.17-13.75) | 1.27 (0.64-3.63) |
| No                                                  | 2.46 (0.51-15.25) |     | 4.52 (0.99-15.25) | 1.33 (0.51-6.87) |
| BMI, kg/m²                                          |                |     |       |               |               |
| < 30                                                 | 2.37 (0.62-15.25) |     | 4.45 (1.08-15.25) | 1.31 (0.62-6.87) |
| ≥ 30                                                 | 2.25 (0.51-9.62) |     | 4.27 (0.99-9.62) | 1.39 (0.51-4.46) |
| **Tumor characteristic**                            |                |     |       |               |               |
| Pathologic T stage                                   |                |     |       |               |               |
| T1                                                  | 2.31 (0.64-15.25) |     | 4.40 (0.99-15.25) | 1.31 (0.64-6.87) |
| T ≥ 2                                               | 2.55 (0.51-12.68) |     | 4.48 (1.08-12.68) | 1.31 (0.51-4.46) |
| Unknown                                             | 1.35 (0.93-8.64) |     | 4.91 (1.17-8.64) | 1.35 (0.93-2.04) |
| Pathologic N stage                                   |                |     |       |               |               |
| N0+                                                 | 2.38 (0.62-15.25) |     | 4.42 (0.99-15.25) | 1.31 (0.62-6.87) |
| N1                                                  | 2.17 (0.51-11.14) |     | 4.22 (1.33-11.14) | 1.22 (0.51-4.12) |
| N2                                                  | 4.20 (1.17-8.55) |     | 6.17 (2.35-8.55) | 1.80 (1.17-6.46) |
| N3                                                  | 2.99 (1.31-8.06) |     | 6.02 (4.96-8.06) | 1.93 (1.31-2.99) |
| Nx/unknown                                          | 1.70 (0.93-8.64) |     | 3.23 (1.17-8.64) | 1.35 (0.93-2.08) |
| **Treatment of BC**                                  |                |     |       |               |               |
| Chemotherapy¶                                       |                |     |       |               |               |
| Yes                                                 | 2.62 (0.51-13.75) |     | 4.68 (1.08-13.75) | 1.34 (0.51-4.46) |
| No                                                  | 2.30 (0.62-15.25) |     | 4.30 (0.99-15.25) | 1.28 (0.62-6.87) |
| Hormonal therapy                                    |                |     |       |               |               |
| Yes                                                 | 2.58 (0.63-13.75) |     | 4.45 (1.17-13.75) | 1.33 (0.63-6.60) |
| No                                                  | 2.29 (0.51-15.25) |     | 4.43 (0.99-15.25) | 1.28 (0.51-6.87) |
### Table A1. MHD in Relation to Patient Clinical Characteristics at Baseline (continued)

| Characteristic | MHD Median (range) | Left-Sided BC | Right-Sided BC |
|---------------|-------------------|---------------|---------------|
|               | Total             | Left-Sided BC | Right-Sided BC |
| RT            |                   |               |               |
| Yes           | 4.11 (1.17-10.81) | 6.17 (2.35-10.81) | 1.79 (1.17-4.46) |
| No            | 2.29 (0.51-15.25) | 4.29 (0.99-15.25) | 1.27 (0.51-6.87) |

Abbreviations: ACE, acute coronary event; BC, breast cancer; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MHD, mean heart dose; RT, radiotherapy.

*Risk factors according to Darby et al included: history of ischemic heart disease, history of circulatory disease other than ischemic heart disease, history of diabetes, history of COPD, current smoker, and BMI $\geq 30$ kg/m$^2$. ACE was defined according to Darby et al as a diagnosis of myocardial infarction (International Classification of Diseases, 10th Revision, codes 121 to 124), coronary revascularization, or death resulting from ischemic heart disease (codes 120 to 125).

†Women with a history of ischemic heart disease were defined as those for whom myocardial infarction or angina was documented in their medical record.

‡Hypertension was considered when the systolic blood pressure was $\geq 140$ mmHg and/or when the diastolic blood pressure was $\geq 90$ mmHg.

§COPD of any Global Initiative on Obstructive Lung Disease class.

¶Diabetes of any type.

‖Adjuvant systemic therapy was indicated in patients with high-risk node-negative tumors and in patients with node-positive disease. In 55 patients, detailed information about chemotherapy treatment was not clearly registered. In total, 248 patients received anthracyclines. In this series, 26 patients were treated with taxane-based chemotherapy. Trastuzumab (n = 47) was recommended for all patients with tumors overexpressing the human epidermal growth factor receptor 2.
### Table A2. Detailed Information on All Patients With BC With ACE at Baseline

| Variable | No of Risk Factors for ACE* | History of Combined Comorbidity | Lifestyle Risk Factor | Tumor Characteristic | Treatment for BC | RT |
|----------|-----------------------------|---------------------------------|----------------------|---------------------|------------------|----|
| Patient  | Age at BC Diagnosis (years) | Time of ACE After Start of RT (years) | Ischemic Heart Disease | Heart Failure | Cardiac Value Disease | Myocarditis, Endocarditis, and/or Pericarditis | Hypertension | COPD | Pulmonary Embolism | Diabetes | BMI < 30 kg/m² | BMI ≥ 30 kg/m² | Pathologic Stage | Pathologic N Stage | BC Lateral | Chemotherapy | Hormonal Therapy | MHD | LV V5 | Regional RT |
| 1 | 59 | 6.7 | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 6.39 | 76.83 | — |
| 2 | 70 | 6.0 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Right | — | — | 0.87 | 0.00 | — |
| 3 | 81 | 0.5 | — | X | — | — | — | — | — | X | — | — | T1 | N0 | Left | — | — | 3.45 | 28.77 | — |
| 4 | 60 | 1.3 | — | X | X | — | — | — | X | — | — | — | T1 | N0 | Right | — | — | 1.10 | 0.00 | — |
| 5 | 70 | 4.0 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 3.73 | 21.63 | — |
| 6 | 75 | 4.6 | — | X | — | X | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 3.22 | 31.37 | — |
| 7 | 71 | 6.1 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 4.27 | 23.94 | — |
| 8 | 73 | 3.8 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Right | — | — | 1.95 | 0.00 | — |
| 9 | 73 | 1.7 | — | X | X | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 1.21 | 0.00 | — |
| 10 | 72 | 5.4 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Right | — | — | 0.89 | 0.00 | — |
| 11 | 72 | 5.8 | — | X | X | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 4.40 | 30.75 | — |
| 12 | 74 | 1.7 | — | X | X | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 4.37 | 50.49 | — |
| 13 | 49 | 5.2 | — | X | — | — | — | — | — | X | X | — | — | T1 | N0 | Right | — | — | 1.15 | 0.00 | — |
| 14 | 63 | 2.0 | — | X | X | — | — | — | X | X | — | — | T1 | N0 | Right | — | — | 1.36 | 0.00 | — |
| 15 | 74 | 8.8 | — | X | X | — | — | — | X | X | — | — | T1 | N0 | Left | — | — | 2.86 | 7.29 | — |
| 16 | 66 | 6.1 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Right | — | — | 0.93 | 0.00 | — |
| 17 | 63 | 0.6 | — | X | X | — | — | — | X | X | — | — | T1 | N0 | Left | — | — | 8.92 | 64.57 | — |
| 18 | 73 | 0.8 | — | X | — | X | — | — | X | X | — | — | T > 2 | N0 | Left | — | — | 5.92 | 29.53 | — |
| 19 | 68 | 6.0 | — | X | — | — | — | — | — | X | X | — | — | T1 | N0 | Right | — | — | 1.09 | 0.00 | — |
| 20 | 51 | 6.7 | — | X | X | — | — | — | X | X | — | — | T > 2 | N0 | Left | — | — | 11.23 | 100.00 | — |
| 21 | 74 | 2.1 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 6.41 | 37.66 | — |
| 22 | 70 | 0.4 | — | X | — | — | — | — | — | X | — | — | — | T1 | N0 | Left | — | — | 3.72 | 24.11 | — |
| 23 | 60 | 1.0 | — | X | X | — | — | — | X | X | — | — | T1 | N0 | Right | — | — | 0.74 | 0.00 | — |
| 24 | 79 | 3.7 | — | X | X | — | — | — | X | X | — | — | T > 2 | N0 | Left | — | — | 5.62 | 64.23 | — |
| 25 | 67 | 3.2 | X | — | — | — | — | — | — | X | — | — | — | T1 | N1 | Left | — | — | 1.64 | 0.40 | — |
| 26 | 66 | 6.7 | — | X | X | — | — | — | X | X | — | — | T > 2 | N1 | Right | — | — | 0.67 | 0.00 | — |
| 27 | 52 | 3.4 | — | X | — | — | — | — | — | X | — | — | — | T1 | N1 | Left | X | X | 6.04 | 35.86 | — |
| 28 | 33 | 9.8 | — | X | — | — | — | — | — | X | X | — | — | T > 2 | N1 | Left | X | X | 4.85 | 49.30 | — |
| 29 | 72 | 2.3 | — | X | X | — | — | — | X | X | — | — | T > 2 | N2 | Left | X | — | 6.32 | 56.40 | X |
| 30 | 63 | 4.7 | — | X | — | — | — | — | — | X | — | — | — | T > 2 | N2 | Left | X | X | 7.26 | 77.43 | X |

**Abbreviations:** ACE, acute coronary event; BC, breast cancer; BMI, body mass index; COPD, chronic obstructive pulmonary disease; LV-V5, left ventricle receiving 5 Gy; MHD, mean heart dose; RT, radiotherapy.

*Risk factors at baseline according to Darby et al included: history of ischemic heart disease, history of circulatory disease other than ischemic heart disease, history of diabetes, history of COPD, current smoker, and BMI ≥ 30 kg/m². ACE was defined according to Darby et al as a diagnosis of myocardial infarction (International Classification of Diseases, 10th Revision, codes 121 to 124), coronary revascularization, or death resulting from ischemic heart disease (codes 120 to 125).

†Women with a history of ischemic heart disease were defined as those for whom myocardial infarction or angina was documented in their medical record.

‡Hypertension was considered when the systolic blood pressure was ≥ 140 mmHg and/or when the diastolic blood pressure was ≥ 90 mmHg.

§COPD of any Global Initiative on Obstructive Lung Disease class.

ffull systemic therapy was indicated in patients with high-risk node-negative tumors and in patients with node-positive disease.

fRelative volume of LV-V5 based on individual three-dimensional dose-volume data obtained from computed tomography planning scans.
Female patients with BC treated with RT after breast-conserving surgery for stage I to III invasive adenocarcinoma or carcinoma in situ from January 2005 to December 2008 (N = 1,137)

Excluded
- History of malignancy, prior thoracic RT, or treatment with neoadjuvant chemotherapy (n = 105)
- CT-based RT planning data unavailable (n = 122)

Analyzed
- Patient cases (those who developed an ACE) (n = 30)
- Noncases (those who did not) (n = 880)

**Fig A1.** Study population flowchart. ACE, acute coronary event; BC, breast cancer; CT, computed tomography; RT, radiotherapy.

**Fig A2.** Distribution of mean heart dose (MHD) for the entire population (N = 910; median MHD, 2.37; standard deviation, 2.26; range, 0.51 to 15.25).
Fig A3. Distribution of mean heart dose (MHD) for left-sided breast cancer (n = 451; median MHD, 4.44; standard deviation, 2.12; range, 0.99 to 15.25).

Fig A4. Distribution of mean heart dose (MHD) for right-sided breast cancer (n = 459; median MHD, 1.31; standard deviation, 0.72; range, 0.51 to 6.87).
Fig A5. Relationship between mean heart dose (MHD) and percentage of acute coronary events (ACEs) based on univariable analysis (i.e., not corrected for age or presence of cardiovascular risk factors). The linear trend line crosses the y-axis, indicating ACEs not related to radiotherapy. Vertical bars indicate 95% CIs.

Fig A6. Cumulative incidence of acute coronary events (ACEs) in the entire population; vertical bars indicate 95% CIs. RT, radiotherapy.